Temasek-backed vaccine developer Recbio raises $98m in Hong Kong IPO

Temasek-backed vaccine developer Recbio raises $98m in Hong Kong IPO

31 March, 2022

COVID-19 HPV Jiangsu Recbio Technology vaccine

Printed by Unregistered user on Tue, 22 Jul 2025 08:49:08 GMT

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

Subscribe to Newsletter

You may also like

China's COVID-19 vaccine developer Clover raises $240m in HK IPO

China's mRNA vaccine technology firm Abogen nabs over $700m

Read more from Greater China

Venture Capital

Startup funding in Greater China grows 13% in Q2 on Ximalaya’s $2.4b deal

Cannot rely solely on valuation metrics for AI investments: Cathay Innovation